1. Home
  2. APAM vs CELC Comparison

APAM vs CELC Comparison

Compare APAM & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Artisan Partners Asset Management Inc.

APAM

Artisan Partners Asset Management Inc.

HOLD

Current Price

$41.08

Market Cap

2.9B

Sector

Finance

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$99.41

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APAM
CELC
Founded
1994
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
3.1B
IPO Year
2013
2017

Fundamental Metrics

Financial Performance
Metric
APAM
CELC
Price
$41.08
$99.41
Analyst Decision
Buy
Strong Buy
Analyst Count
4
8
Target Price
$47.00
$100.13
AVG Volume (30 Days)
507.5K
883.6K
Earning Date
02-03-2026
11-12-2025
Dividend Yield
8.71%
N/A
EPS Growth
2.95
N/A
EPS
3.71
N/A
Revenue
$1,158,234,000.00
N/A
Revenue This Year
$8.38
N/A
Revenue Next Year
$6.56
N/A
P/E Ratio
$11.25
N/A
Revenue Growth
8.88
N/A
52 Week Low
$32.75
$7.58
52 Week High
$48.50
$112.64

Technical Indicators

Market Signals
Indicator
APAM
CELC
Relative Strength Index (RSI) 40.79 54.37
Support Level $41.50 $98.76
Resistance Level $42.04 $103.09
Average True Range (ATR) 0.69 4.13
MACD 0.05 -1.19
Stochastic Oscillator 47.79 16.85

Price Performance

Historical Comparison
APAM
CELC

About APAM Artisan Partners Asset Management Inc.

Artisan Partners Asset Management Inc is a investment management firm providing a range of investment strategies to a diverse group of clients around the world. Each of the company's strategies is managed by one of its several investment teams. Investment management services are offered to institutions through separate accounts and mutual funds. Artisan's investment offerings include several long-only, equity investment strategies across a multitude of market capitalization segments and investing styles in both the United States and international markets. In addition to its equity strategies, customers may invest in a fixed-income strategy. Strategies are often distributed to customers ranging from retail investors to institutional investors through specialized channels.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: